# Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

> **NCT01967940** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 55 (actual)

## Conditions studied

- HIV
- HIV Infections
- Acquired Immunodeficiency Syndrome

## Interventions

- **DRUG:** TAF
- **DRUG:** Placebo
- **DRUG:** E/C/F/TAF
- **DRUG:** Current failing ARV regimen
- **DRUG:** ATV

## Key facts

- **NCT ID:** NCT01967940
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-25
- **Primary completion:** 2015-05-21
- **Final completion:** 2017-07-31
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01967940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01967940, "Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01967940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*